Discovery of a new class of cell‑penetrating peptides by novel phage display platform

DOI: 10.1038/s41598-024-64405-wCentral Idea: Researchers developed a novel phage display platform called NNJA (Novel peptides for intracellular delivery by hijacking two cell systems) that discovers cell-penetrating peptides capable of delivering therapeutic cargo to the cell cytoplasm while avoiding lysosomal degradation. This platform addresses a major challenge in the field of therapeutic delivery.Key Concepts:The NNJA Platform:- Engineered a lysosomal cathepsin substrate within phage protein PIII- Phage that enter lysosomes are cleaved and eliminated from selection- Only phage that successfully reach cytoplasm survive selection process- Results in peptides optimized for cytoplasmic deliveryNovel CPP Characteristics:- Nine amino acids in length- Lack the typical positive charge clusters of traditional CPPs- Contain specific enriched amino acids: * Methionine/Leucine at first position * Serine/Threonine at second position * Proline in middle and C-terminus- Show efficient cellular uptake without significant toxicityExperimental Validation:- Demonstrated delivery of various cargoes: * siRNA (achieved significant gene knockdown) * Antibodies * Proteins * Reporter molecules- Verified cytoplasmic localization through confocal microscopy- Tested across multiple cell types- Showed comparable or superior performance to traditional CPPs like TATFuture Applications/Implications:Research Applications:- Platform can be adapted for tissue-specific delivery- Potential for targeting specific cellular compartments- Discovery of novel peptide sequences for various therapeutic cargoesTherapeutic Potential:- Improved delivery of oligonucleotides- Enhanced antibody internalization- Possible applications in protein therapeutics- Potential for oral delivery systemsFurther Research/Challenges:Technical Considerations:- Optimizing peptide sequences for specific applications- Understanding exact mechanisms of cell entry- Improving tissue selectivity- Scaling up synthesis and conjugation processesDevelopment Needs:- In vivo validation studies- Stability and pharmacokinetic analysis- Tissue-specific targeting strategies- Investigation of cargo size limitationsBroad Impact: This work provides a new tool for discovering CPPs that could significantly improve the delivery of therapeutic molecules, particularly for challenging intracellular targets. The platform's flexibility and the novel characteristics of the discovered peptides open new possibilities in drug delivery research.